# City Therapeutics files for initial public offering

_Published Friday, September 25, 2026 at 12:20 AM EDT · Capital, Products · Latest · Tier 2 — Notable_

City Therapeutics filed a registration statement for an initial public offering of its common stock on September 24. The clinical-stage biotechnology company has applied to list on the Nasdaq Global Market under the symbol CTY. Its preliminary prospectus leaves the share count and proposed price range blank.

City develops treatments that use RNA interference to suppress production of proteins linked to disease. Its lead candidate, CITY-FXI, is in early clinical development; its other programs are earlier stage. The company has not completed a clinical trial or generated product sales.

## Sources

- [SEC EDGAR](https://www.sec.gov/Archives/edgar/data/2143850/000110465926110430/tm2619715-5_s1.htm)

---
Canonical: https://techandbusiness.org/newswire/uXlzGlz8EknT8aDfW9IyJ2
Published: 2026-09-25T04:20:33.070Z
Story chronology: 2026-09-24T12:00:00.000Z
Retrieved: 2026-09-25T05:54:46.886Z
Publisher: Tech & Business (techandbusiness.org)